Business
Harvest One continues to add bench strength to its international team
Harvest One continues to add bench strength to its international team Canada NewsW...
About this update from Delivra Health Brands Inc
[{"type":"text","content":"\n\n\n\nHarvest One continues to add bench strength to its international team\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Sept. 28, 2018\n\n\n\nTSXV – HVT                                                                                                                  \n VANCOUVER, Sept. 28, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV:HVT) (\"Harvest One\" or the \"Company\") is pleased to announce it is adding four seasoned executives to its Board of Directors, Advisory Board and Senior Leadership Team as it continues to strengthen the H1 team on its mission to become a trusted global leader in developing and providing innovative lifestyle and wellness products to consumers in regulated markets around the world.\n\n \n \n\n \nFrank Holler, President and CEO of Ponderosa Capital Inc., joins the Harvest One Board of Directors.  An expert in biotechnology, investment banking and venture capital, Mr. Holler previously served as CEO and Partner of Lions Capital Corp., fund manager for BC Advantage Funds and the Lions Funds; as President and CEO of Xenon Pharmaceuticals Inc., a private genomics-based drug development company; as President and CEO of ID Biomedical Corporation, a vaccine development company sold to GlaxoSmithKline plc; and as a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed medical device company. Before working in biotechnology and healthcare, Mr. Holler was an Investment Banker with Merrill Lynch Canada ...